Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 1:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 1,859 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo IV infusion Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers

Pgp Transporter and CNS Biodistribution of Ondansetron in Healthy Volunteers

NCT03809234
View directory record Official record
Conditions
Neuropathic Pain
Interventions
Ondansetron 8mg with Saline & Tariquidar, Ondansetron 16mg with Saline & Tariquidar
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 15, 2026, 1:55 PM EDT
Completed Phase 2 Interventional Results available

To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adults With Moderate-to-severe Atopic Dermatitis

NCT02683928
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
GBR 830, Placebo
Biological
Lead sponsor
Ichnos Sciences SA
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
12
States / cities
Rogers, Arkansas • Los Angeles, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Oct 15, 2026, 1:55 PM EDT
Completed Phase 2 Interventional Results available

A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine

NCT03560245
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Bryostatin, Placebo
Drug · Other
Lead sponsor
Neurotrope Bioscience, Inc.
Industry
Eligibility
55 Years to 85 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
28
States / cities
Fresno, California • Los Alamitos, California • Santa Ana, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2020 · Synced Oct 15, 2026, 1:55 PM EDT
Completed Phase 2 Interventional

A Study of Multiple Doses of AbGn-168H by Intravenous Infusion in Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT02223039
View directory record Official record
Conditions
Moderate to Severe Chronic Plaque Psoriasis
Interventions
AbGn-168H, Placebo
Biological
Lead sponsor
AbGenomics B.V Taiwan Branch
Industry
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
15
States / cities
Phoenix, Arizona • Rogers, Arkansas • Ocala, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 15, 2026, 1:55 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Aprepitant to Mitigate Opioids' Cognitive Side Effects

NCT02226601
View directory record Official record
Conditions
Cognitive Dysfunction
Interventions
Aprepitant, Placebo
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Oct 15, 2026, 1:55 PM EDT
Active, not recruiting Phase 2 Interventional

Safety, PK and PD Relationships of RLS-0071 in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

NCT06175065
View directory record Official record
Conditions
Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Interventions
RLS-0071, Placebo
Drug
Lead sponsor
ReAlta Life Sciences, Inc.
Industry
Eligibility
30 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
St. Petersburg, Florida • Glen Burnie, Maryland • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 15, 2026, 1:55 PM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer

NCT00537381
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Docetaxel, Prednisone, Intetumumab, Placebo
Drug · Biological
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
7
States / cities
Birmingham, Alabama • Los Angeles, California • San Bernardino, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 15, 2026, 1:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of E2025 in Healthy Participants

NCT05726851
View directory record Official record
Conditions
Healthy Volunteers
Interventions
E2025, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Oct 15, 2026, 1:55 PM EDT
Completed Phase 3 Interventional Results available

PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study

NCT00911170
View directory record Official record
Conditions
Cancer, Colon Cancer, Colorectal Cancer, Fever, Locally Advanced, Metastatic Colorectal Cancer, Neutropenia, Rectal Cancer
Interventions
Pegfilgrastim, Placebo, Bevacizumab, Standard Chemotherapy
Drug · Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
847 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
72
States / cities
Muscle Shoals, Alabama • Jonesboro, Arkansas • Anaheim, California + 66 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2017 · Synced Oct 15, 2026, 1:55 PM EDT
Completed Phase 1 Interventional

Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) - Alcohol Interaction Study

NCT04827056
View directory record Official record
Conditions
Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD)
Interventions
Placebo, Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg, Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg, Ethanol Infusion, PTSD Reactivity Condition, Alcohol Cue Reactivity
Drug · Procedure · Behavioral
Lead sponsor
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
Other
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 15, 2026, 1:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Japanese and Caucasian Subjects to Assess the Pharmacokinetics, Safety and Tolerability of Risankizumab

NCT05305222
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Risankizumab, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 15, 2026, 1:55 PM EDT
Completed Phase 3 Interventional Results available

Acid Lipase Replacement Investigating Safety and Efficacy (ARISE) in Participants With Lysosomal Acid Lipase Deficiency

NCT01757184
View directory record Official record
Conditions
Lysosomal Acid Lipase Deficiency
Interventions
Sebelipase Alfa, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
4 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
11
States / cities
Tucson, Arizona • Palo Alto, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Oct 15, 2026, 1:55 PM EDT
Completed Phase 2 Interventional

Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)

NCT04295538
View directory record Official record
Conditions
Spinal Cord Injury (SCI)
Interventions
Elezanumab, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
22
States / cities
Sacramento, California • Atlanta, Georgia • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 15, 2026, 1:55 PM EDT
Active, not recruiting Phase 2 Interventional

Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus

NCT05039840
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
SAR441344 IV, SAR441344 SC, Placebo IV, Placebo SC
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
22
States / cities
Vestavia Hills, Alabama • Chandler, Arizona • Mesa, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 15, 2026, 1:55 PM EDT
Completed Phase 2 Interventional Results available

REduCing Immunogenicity to PegloticasE (RECIPE) Study

NCT03303989
View directory record Official record
Conditions
Gout Chronic
Interventions
Pegloticase 8 MG/ML [Krystexxa], MMF, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 15, 2026, 1:55 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD)

NCT00562497
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Prochymal®, Placebo, Corticosteroid
Drug · Other
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
45
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Oct 15, 2026, 1:55 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and PK of AH-008 Following Single Ascending Dose in Healthy Subjects

NCT07697560
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy (CIPN)
Interventions
AH-008 for Injection, 150 mg, AH-008 for Injection, Placebo
Drug
Lead sponsor
AnHorn Medicines Co. Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 15, 2026, 1:55 PM EDT
Recruiting Phase 3 Interventional

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

NCT06256588
View directory record Official record
Conditions
Neoplasms, Head and Neck
Interventions
Dostarlimab, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
36
States / cities
Jonesboro, Arkansas • Los Angeles, California • Solvang, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 15, 2026, 1:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study of WAL0921 in Healthy Subjects

NCT05891366
View directory record Official record
Conditions
Healthy
Interventions
WAL0921, Placebo
Drug
Lead sponsor
Walden Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Oct 15, 2026, 1:55 PM EDT
Completed Phase 3 Interventional Results available

Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis)

NCT00145327
View directory record Official record
Conditions
Osteoporosis
Interventions
Zoledronic Acid, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
68 Years to 90 Years · Female only
Enrollment
2,456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
30
States / cities
Tucson, Arizona • Little Rock, Arkansas • Beverly Hills, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2011 · Synced Oct 15, 2026, 1:55 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

NCT04191096
View directory record Official record
Conditions
Metastatic Hormone-Sensitive Prostate Cancer
Interventions
Pembrolizumab, Enzalutamide, Androgen Deprivation Therapy (ADT), Placebo
Biological · Drug · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
27
States / cities
Anchorage, Alaska • Duarte, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 15, 2026, 1:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study With Healthy Japanese and Non-Asian Participants With BMS-986231

NCT02932969
View directory record Official record
Conditions
Heart Decompensation, Acute
Interventions
BMS-986231, BMS-986231 Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 40 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 15, 2026, 1:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430

NCT03800173
View directory record Official record
Conditions
Marburg Virus Disease
Interventions
galidesivir, placebo
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 15, 2026, 1:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus

NCT01353027
View directory record Official record
Conditions
Ebola Hemorrhagic Fever
Interventions
Placebo, AVI-6002
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 28, 2012 · Synced Oct 15, 2026, 1:55 PM EDT